Phase Ib Trial of Pembrolizumab Administered in Combination With or Following Adoptive Cell Therapy- A Multiple Cohort Study; The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2; Tumour infiltrating lymphocytes
- Indications Malignant melanoma; Ovarian cancer
- Focus Adverse reactions
- Acronyms ACTIVATE
- 26 Sep 2018 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 26 Sep 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.